BioLife Options, Inc. (NASDAQ:BLFS – Get Rating) was the recipient of a big decline in brief curiosity in December. As of December fifteenth, there was quick curiosity totalling 2,530,000 shares, a decline of 17.9% from the November thirtieth whole of three,080,000 shares. Primarily based on a mean each day buying and selling quantity, of 376,100 shares, the days-to-cover ratio is presently 6.7 days. Presently, 6.4% of the corporate’s inventory are offered quick.
Analyst Upgrades and Downgrades
Quite a lot of equities analysis analysts not too long ago weighed in on the inventory. Stephens lowered their value goal on shares of BioLife Options to $31.00 in a analysis report on Wednesday, November sixteenth. StockNews.com raised shares of BioLife Options to a “promote” score in a analysis report on Monday, November twenty first.
BioLife Options Worth Efficiency
NASDAQ BLFS traded up $0.06 on Friday, hitting $18.20. The inventory had a buying and selling quantity of 188,935 shares, in comparison with its common quantity of 355,078. BioLife Options has a one yr low of $10.40 and a one yr excessive of $38.69. The corporate has a debt-to-equity ratio of 0.06, a present ratio of three.68 and a fast ratio of two.76. The corporate’s 50-day shifting common is $20.44 and its two-hundred day shifting common is $20.42.
BioLife Options (NASDAQ:BLFS – Get Rating) final posted its earnings outcomes on Wednesday, November ninth. The medical gear supplier reported ($0.15) EPS for the quarter, lacking the consensus estimate of ($0.12) by ($0.03). The agency had income of $40.75 million in the course of the quarter, in comparison with the consensus estimate of $41.63 million. BioLife Options had a unfavorable return on fairness of seven.50% and a unfavorable internet margin of 67.70%. On common, equities analysts predict that BioLife Options will submit -0.63 earnings per share for the present fiscal yr.
Insiders Place Their Bets
In different BioLife Options information, COO Greef Roderick De offered 8,552 shares of the enterprise’s inventory in a transaction on Friday, October seventh. The shares have been offered at a mean value of $22.69, for a complete worth of $194,044.88. Following the transaction, the chief working officer now owns 116,719 shares within the firm, valued at roughly $2,648,354.11. The sale was disclosed in a doc filed with the Securities & Change Fee, which is accessible by way of this link. In different information, Director Amy Duross offered 2,600 shares of the enterprise’s inventory in a transaction dated Tuesday, November fifteenth. The shares have been offered at a mean value of $24.35, for a complete worth of $63,310.00. Following the completion of the sale, the director now owns 18,157 shares of the corporate’s inventory, valued at roughly $442,122.95. The transaction was disclosed in a authorized submitting with the Securities & Change Fee, which is on the market by way of the SEC website. Additionally, COO Greef Roderick De offered 8,552 shares of the enterprise’s inventory in a transaction dated Friday, October seventh. The inventory was offered at a mean value of $22.69, for a complete transaction of $194,044.88. Following the completion of the sale, the chief working officer now immediately owns 116,719 shares of the corporate’s inventory, valued at roughly $2,648,354.11. The disclosure for this sale will be discovered here. Insiders have offered 99,779 shares of firm inventory price $2,165,239 within the final quarter. 3.30% of the inventory is owned by company insiders.
Institutional Buying and selling of BioLife Options
Institutional traders have not too long ago made adjustments to their positions within the inventory. Allspring World Investments Holdings LLC lifted its stake in shares of BioLife Options by 802.2% within the third quarter. Allspring World Investments Holdings LLC now owns 1,218 shares of the medical gear supplier’s inventory price $27,000 after buying a further 1,083 shares in the course of the interval. Wipfli Monetary Advisors LLC acquired a brand new stake in BioLife Options in the course of the third quarter valued at roughly $29,000. Nisa Funding Advisors LLC lifted its stake in BioLife Options by 439.3% in the course of the third quarter. Nisa Funding Advisors LLC now owns 1,510 shares of the medical gear supplier’s inventory valued at $34,000 after buying a further 1,230 shares over the last quarter. KBC Group NV acquired a brand new stake in BioLife Options in the course of the second quarter valued at roughly $36,000. Lastly, Point72 Hong Kong Ltd acquired a brand new stake in shares of BioLife Options in the course of the first quarter valued at roughly $36,000. 89.82% of the inventory is owned by institutional traders and hedge funds.
BioLife Options Firm Profile
BioLife Options, Inc engages within the growth, manufacture and advertising and marketing of bio preservation instruments for cells and tissues. Its product choices embrace proprietary hypothermic storage and cryopreservation freeze media merchandise for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media merchandise and customized product formulation and customized packaging providers.
This prompt information alert was generated by narrative science know-how and monetary information from MarketBeat with the intention to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you think about BioLife Options, you may need to hear this.
MarketBeat retains monitor of Wall Avenue’s top-rated and finest performing analysis analysts and the shares they suggest to their shoppers every day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and BioLife Options wasn’t on the checklist.
Whereas BioLife Options presently has a “Purchase” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.